Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSB462 in Japanese Patients With Metastatic Prostate Cancer
NCT07174063Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2025
- Primary completion
- Jan 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of luxdegalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events and Serious Adverse Events at 18 months and 6 more. Started Nov 2025; status: active, not recruiting.
02
Drugs
luxdegalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07174063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174063.